Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. [Phase 1]

View source ↗

Summary

Pfizer's PF-07799933 is being studied in a Phase 1 trial for advanced solid tumors with BRAF alterations. The study includes melanoma, non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Glioma
• Melanoma
• Non-small Cell Lung Cancer
• Thyroid Cancer

Drugs mentioned

• PF-07799933

Snippet

Sponsor: Pfizer | Conditions: Melanoma, Non-Small-Cell Lung Cancer | Phase 1 | Status: RECRUITING